The genome DNA is constantly exposed to various genotoxic insults. Among the variety of types of DNA damage, the most deleterious is the DNA double-strand break (DSB).([@b1]) Double-strand breaks can be generated by endogenous sources such as reactive oxygen species produced during cellular metabolic processes and replication-associated errors, as well as by exogenous sources including ionizing radiation and chemotherapeutic agents. Double-strand breaks are also generated in a programmed manner during meiosis and during the V(D)J recombination and class switch recombination required for the development of lymphocytes. If left unrepaired, DSBs can result in cell death. If accurately repaired, DSBs can result in survival of cells with no adverse effects. If insufficiently or inaccurately repaired, DSBs can result in survival of cells showing genomic alterations that may contribute to tumor development.([@b2]) In order to maintain genomic integrity, cells have evolved a well coordinated network of signaling cascades, termed the DNA damage response, to sense and transmit the damage signals to effector proteins, and induce cellular responses including cell cycle arrest, activation of DNA repair pathways, and cell death (Fig. [1](#fig01){ref-type="fig"}).([@b1])

![Overview of the diverse spectrum of DNA damage and the DNA damage response. The major repair pathways and key proteins used to process each type of damage are shown. In non-homologous end-joining (NHEJ), the Ku70/Ku80 complex binds to the DNA double-strand break ends and recruits the other indicated components. In base-excision repair (BER), poly(ADP-ribose) polymerase-1 (PARP-1) detects and binds to single-strand breaks and ensures accumulation of other repair factors at the breaks. Single-strand breaks containing modified DNA ends are recognized by damage-specific proteins such as apurinic/apyrimidinic endonuclease (APE1), which subsequently recruits Polβ and XRCC1-DNA ligase IIIα to accomplish the repair. All the molecules indicated here are aberrated in sporadic cancers. The proteins targeted for cancer therapy in the present clinical trials are marked with red asterisks. alt-NHEJ, alternative NHEJ; ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; FA, Fanconi anemia; HR, homologous recombination; MGMT, O^6^-methylguanine-DNA methyltransferase; MMR, mismatch repair; MRN, MRE11--RAD50--NBS1; NER, nucleotide excision repair; TLS, translesion synthesis.](cas0105-0370-f1){#fig01}

Cancer chemotherapeutic agents and radiotherapy exert their cytotoxic effects by inducing DNA DSBs. As cancer cells often have specific abnormalities in the DNA damage response, therapeutic strategies based on such properties of cancer cells have been developed. Several inhibitors that block specific DNA damage responses or repair proteins have been tried not only as sensitizing agents in combination with DNA-damaging agents but also as single agents against cancers with defects in particular DNA repair pathways. The most prominent example of the latter is the killing effect of poly(ADP-ribose) polymerase (PARP) inhibitors on BRCA1- or BRCA2-defective tumors, which takes advantage of the defects in DNA repair in cancer cells.([@b3])

In this review, we will first outline the mechanism of the DNA damage response. Next, we will describe the aberrations in DNA damage responses in human cancers. Finally, we will explain how different DNA damage response pathways can be targeted for cancer therapy.

Mechanism of DNA Damage Response
================================

DNA-damaging agents induce various types of DNA damage including modification of bases, intrastrand crosslinks, interstrand crosslinks (ICL), DNA--protein crosslinks, single-strand breaks (SSBs), and DSBs. Each type of DNA damage is recognized and processed by proteins involved in the DNA damage response (Fig. [1](#fig01){ref-type="fig"}).

In response to DSBs, the MRE11--RAD50--NBS1 (MRN) complex senses and binds to DSB sites, and recruits and activates the ataxia telangiectasia mutated (ATM) kinase through its autophosphorylation.([@b4],[@b5]) Once activated, ATM phosphorylates a large number of downstream proteins.([@b6]) Phosphorylation of Chk2 induces phosphorylation of the protein phosphatase CDC25A, leading to cell cycle arrest. Phosphorylation of BRCA1 leads to DSB repair as well as cell cycle arrest in the S phase, whereas activation of p53 triggers cell cycle arrest in the G~1~ phase or cell death. In the initiation of the response to SSBs or DNA replication fork collapse, the ataxia telangiectasia and Rad3-related (ATR) kinase is activated and recruited to the sites of DNA damage.([@b7]) ATR phosphorylates and activates Chk1,([@b8]) which plays a role in the S and G~2~/M cell checkpoints by regulating the stability of the CDC25 phosphatases. Activation of the 53BP1 protein, a mediator of the DNA damage response, contributes to the choice of the DSB repair pathways by promoting non-homologous end joining (NHEJ).([@b9])

The DNA repair pathways can either work independently or coordinately to repair different types of DNA damage (Fig. [1](#fig01){ref-type="fig"}). Double-strand breaks are predominantly repaired by either NHEJ or homologous recombination (HR).([@b10]) Non-homologous end joining is an error-prone repair pathway that is mediated by the direct joining of the two broken ends.([@b10]) Factors involved in NHEJ include the Ku70/Ku80 complex, DNA-PK catalytic subunit (DNA-PKcs), the Artemis nuclease, XLF, XRCC4, and DNA ligase IV. Homologous recombination is an error-free repair pathway that requires a non-damaged sister chromatid to serve as a template for repair (Fig. [2](#fig02){ref-type="fig"}).([@b10]) Factors involved in HR include the MRN complex, CtIP, replication protein A (RPA), BRCA1, PALB2, BRCA2, and RAD51. In addition to NHEJ and HR, an alternative form of NHEJ, namely, alt-NHEJ, is also involved in DSB repair.([@b11]) It exhibits a slower process than the classical NHEJ and can catalyze the joining of unrelated DNA molecules, leading to the formation of translocations as well as large deletions and other sequence alterations at the junction. Factors involved in this pathway include PARP-1, XRCC1, DNA ligase IIIα, polynucleotide kinase, and Flap endonuclease 1.

![Early steps of homologous recombination. First, the DNA double-strand break is sensed by the MRE11--RAD50--NBS1 (MRN) complex, which subsequently recruits and activates the ataxia telangiectasia mutated (ATM) kinase. Then, the DNA ends are resected by the MRN complex and CtIP, resulting in generation of 3′ single-stranded DNA (ssDNA) overhangs on both sides of the break. These overhangs are coated and stabilized by replication protein A (RPA). Next, BRCA2, which forms the BRCA1--PALB2--BRCA2 complex, directly binds RAD51 and recruits it to the double-stranded DNA--ssDNA junction, and promotes the loading of RAD51 onto ssDNA. This step is followed by displacement of RPA from ssDNA ends and assembly of the RAD51--ssDNA filament, which is mediated by BRCA2, leading to strand invasion into an undamaged homologous DNA template. All the molecules indicated here are aberrated in sporadic cancers. None of the proteins indicated here are targeted for cancer therapy in the present clinical trials. P, phosphorylation.](cas0105-0370-f2){#fig02}

Single-strand breaks and subtle changes to DNAs are repaired using base-excision repair (BER) proteins,([@b12]) which include PARP-1, XRCC1, DNA ligase IIIα, and apurinic/apyrimidinic endonuclease (APE1). Bulky DNA lesions such as pyrimidine dimers caused by UV irradiation are processed by the nucleotide excision repair (NER) pathway,([@b13]) which requires the excision repair cross-complementing protein 1 (ERCC1). Base mismatches arising as a result of replication errors can be repaired by the mismatch repair pathway.([@b14])

In the repair of ICL, ubiquitin-mediated activation of the Fanconi anemia (FA) pathway plays a key role.([@b15]) The FA pathway is constituted by at least 15 FA gene products, whose germline defects result in FA, a cancer predisposition syndrome. Activation of the FA core complex, which is comprised of eight FA proteins (FANCA/B/C/E/F/G/L/M) and associated proteins, leads to monoubiquitination of FANCD2 and FANCDI, which subsequently coordinates three critical DNA repair processes, including nucleolytic incision by XPF-ERCC1 and SLX4 endonucleases, translesion DNA synthesis, and HR.

Aberrations in DNA Damage Responses in Human Cancers
====================================================

In sporadic cancers, both activation and inactivation of the DNA damage response are found in various cancers,([@b16]--[@b62]) as summarized in Table [1](#tbl1){ref-type="table"}.

###### 

Examples of aberrations in DNA damage responses in human sporadic cancers

  Molecule                                                                  Activation or inactivation                                   Type of aberrations                                                                                             Type(s) of cancer                                                                                                                                           Frequency          Phenotypes                                    Reference(s)
  ------------------------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ --------------------------------------------- -------------------------
  ATM                                                                       Activation                                                   Increased autophosphorylation                                                                                   Bladder, breast cancers                                                                                                                                     30--68%            Cancer barrier function                       ([@b16],[@b18])
  Increased copy number                                                     Prostate cancers                                             ˜2%                                                                                                                                                                                                                                                                         ([@b51])                                                         
  Inactivation                                                              Mutation                                                     Pancreatic, lung, colon, endometrial, prostate, skin, kidney, breast, central nervous system, ovarian cancers   1--7%                                                                                                                                                                          ([@b49],[@b50])                               
  Hematopoietic and lymphoid malignancies                                   ˜11%                                                                                                                                                                         ([@b49])                                                                                                                                                                                                                     
  Loss of heterozygosity, loss                                              Pancreatic cancers                                           ˜5%                                                                                                                                                                                                                                                                         ([@b50])                                                         
  Decreased copy number                                                     Prostate cancers                                             ˜5%                                                                                                                                                                                                                                                                         ([@b51])                                                         
  Decreased expression                                                      Breast, head and neck cancers                                25--75%                                                                                                                                                                                                                                                                     ([@b54],[@b55])                                                  
  MRE11                                                                     Inactivation                                                 Decreased expression                                                                                            Breast cancers                                                                                                                                              7--31%                                                           ([@b19],[@b54],[@b56])
  Colorectal, gastric, pancreatic cancers with microsatellite instability   67--100%                                                                                                                                                                     ([@b19])                                                                                                                                                                                                                     
  RAD50                                                                     Activation                                                   Increased expression                                                                                            Colorectal cancers                                                                                                                                          ˜24%                                                             ([@b21])
  Inactivation                                                              Decreased expression                                         Breast cancers                                                                                                  3--28%                                                                                                                                                                         ([@b19],[@b54],[@b56])                        
  Colorectal, gastric cancers with microsatellite instability               28--71%                                                                                                                                                                      ([@b19])                                                                                                                                                                                                                     
  NBS1                                                                      Activation                                                   Increased expression                                                                                            Esophageal, head and neck, non-small-cell lung cancers, hepatomas                                                                                           40--52%            Poor prognosis                                ([@b19],[@b20])
  Inactivation                                                              Decreased expression                                         Breast cancers                                                                                                  10--46%                                                                                                                                                                        ([@b19],[@b54],[@b56])                        
  Chk1                                                                      Activation                                                   Increased phosphorylation                                                                                       Cervical cancers                                                                                                                                            ˜25%                                                             ([@b27])
  Increased expression                                                      Lung, liver, breast, colorectal, ovarian, cervical cancers   46--100%                                                                                                        Resistance to chemotherapy, poor prognosis                                                                                                                  ([@b22]--[@b27])                                                 
  Inactivation                                                              Decreased expression                                         Lung, ovarian cancers, hetapocellular carcinomas                                                                9--32%                                                                                                                                                                         ([@b22],[@b23],[@b26])                        
  Chk2                                                                      Activation                                                   Increased phosphorylation                                                                                       Bladder, colon, lung cancers, melanomas                                                                                                                     30--50%            Cancer barrier function                       ([@b16],[@b17])
  Increased expression                                                      Ovarian cancers                                              ˜37%                                                                                                                                                                                                                                                                        ([@b26])                                                         
  Inactivation                                                              Decreased expression                                         Breast, non-small cell lung cancers                                                                             28--47%                                                                                                                                                                        ([@b57],[@b58])                               
  p53                                                                       Inactivation                                                 Mutation                                                                                                        Solid tumors                                                                                                                                                ˜50%                                                             ([@b47])
  Hematopoietic malignancies                                                ˜10%                                                                                                                                                                         ([@b47])                                                                                                                                                                                                                     
  Decreased expression                                                      Solid and hematopoietic tumors                               ˜50%                                                                                                            Resistance to chemotherapy, poor prognosis                                                                                                                  ([@b48])                                                         
  CDC25A                                                                    Activation                                                   Increased expression                                                                                            Thyroid, breast, ovarian, liver, colorectal, laryngeal, esophageal cancers, non-Hodgkin\'s lymphomas                                                        17--70%                                                          ([@b28])
  CDC25B                                                                    Activation                                                   Increased expression                                                                                            Thyroid, breast, ovarian, liver, gastric, colorectal, laryngeal, esophageal, endometrial, prostate cancers, gliomas, non-Hodgkin\'s lymphomas               20--79%                                                          ([@b28])
  CDC25C                                                                    Activation                                                   Increased expression                                                                                            Colorectal, endometrial cancers, non-Hodgkin\'s lymphomas                                                                                                   13--27%                                                          ([@b28])
  DNA-PKcs                                                                  Activation                                                   Increased expression                                                                                            Glioblastoma, prostate cancers                                                                                                                              ˜49%               Poor survival                                 ([@b29],[@b30])
  RAD51                                                                     Activation                                                   Increased expression                                                                                            Breast, head and neck, non-small-cell lung cell, pancreatic cancers, soft tissue sarcomas                                                                   24--66%            Resistance to platinum agents, poor outcome   ([@b31]--[@b35])
  Inactivation                                                              Decreased expression                                         Breast, colorectal cancers                                                                                      ˜30%                                                                                                                                                                           ([@b59],[@b60])                               
  BRCA1                                                                     Activation                                                   Increased expression                                                                                            Lung cancers                                                                                                                                                ˜22%               Resistance to chemotherapy                    ([@b36])
  Inactivation                                                              Mutation                                                     Breast, ovarian cancers                                                                                         \<10%                                                                                                                                                                          ([@b52],[@b53])                               
  Decreased expression                                                      Breast, ovarian, lung cancers                                9--30%                                                                                                                                                                                                                                                                      ([@b60]--[@b62])                                                 
  BRCA2                                                                     Inactivation                                                 Mutation                                                                                                        Breast, ovarian cancers                                                                                                                                     \<10%                                                            ([@b52],[@b53])
  Decreased expression                                                      Ovarian cancers                                              13%                                                                                                                                                                                                                                                                         ([@b61])                                                         
  ERCC1                                                                     Activation                                                   Increased expression                                                                                            Colorectal, ovarian, gastric, head and neck, non-small-cell lung cancers                                                                                    14--70%            Resistance to platinum agents                 ([@b31],[@b37]--[@b43])
  Inactivation                                                              Decreased expression                                         Colorectal, gastric, non-small-cell lung cancers                                                                30--77%                                                                                                                                                                        ([@b37],[@b38],[@b42],[@b43])                 
  APE1                                                                      Activation                                                   Increased expression                                                                                            Bladder, breast, cervical, head and neck, liver, non-small-cell lung cancers, ovarian cancers, medulloblastomas, gliomas, osteosarcomas, germ cell tumors   19--99%            Resistance to chemotherapy and/or radiation   ([@b44])
  PARP                                                                      Activation                                                   Increased expression                                                                                            Breast cancers, germ cell tumors                                                                                                                            5--47%                                                           ([@b45],[@b46])
  FANCA                                                                     Inactivation                                                 Decreased expression/loss of expression                                                                         Acute myelogenous leukemias                                                                                                                                 4--40%                                                           ([@b64],[@b65])
  Mutation                                                                  Acute myelogenous leukemias                                  ˜7.6%                                                                                                                                                                                                                                                                       ([@b64])                                                         
  FANCC                                                                     Inactivation                                                 Mutation, loss of heterozygosity                                                                                Pancreatic cancers                                                                                                                                          ˜9%                                                              ([@b64])
  FANCF                                                                     Inactivation                                                 Decreased expression/loss of expression                                                                         Breast, cervical, head and neck, non-small-cell lung, ovarian cancers, acute myelogenous leukemias, germ cell tumors                                        6.7˜30%                                                          ([@b64],[@b65])
  FANCG                                                                     Inactivation                                                 Loss of expression                                                                                              Acute myelogenous leukemias                                                                                                                                 27%                                                              ([@b65])

Expression has been confirmed at mRNA and/or protein levels. Studies using cultured cancer cells are excluded.

Regarding activation of the DNA damage response proteins, increased autophosphorylation of ATM and ATM-dependent phosphorylation of Chk2 are reported in early-stage tumors, suggesting that the DNA damage response may serve as a barrier to the malignant progression of tumors.([@b16],[@b17]) In contrast, a recent study reports that ATM is hyperactive in late-stage breast tumor tissues, suggesting that the ATM-mediated DNA damage response also plays a role in tumor progression and metastasis.([@b18]) Increased expression of NBS1, RAD50, Chk1, Chk2, CDC25A, CDC25B, and CDC25C are also reported.([@b19]--[@b28]) DNA-PK catalytic subunit is reported to be upregulated in radiation-resistant tumors or in tumors with poor survival.([@b29],[@b30]) Overexpression of RAD51, BRCA1, ERCC1, APE1, and PARP1 is also observed in various cancers and is associated with resistance to chemotherapy.([@b31]--[@b46])

However, inactivation of DNA damage response proteins is also observed in various cancers. The *p53* gene is one of the most frequently mutated genes in human sporadic cancers. Although the reported frequencies of *p53* mutation vary among the types of cancer, it is estimated that more than half of cancers might have inactivated p53 due to mutations, deletion, loss of heterozygosity of the gene, or decreased expression.([@b47],[@b48]) Although inactivating mutations in *ATM*, *BRCA1,* or *BRCA2* are less frequent than those in the *p53* gene,([@b49]--[@b53]) decreased expression of ATM, the MRN complex, Chk2, RAD51, BRCA1, BRCA2, and ERCC1 is frequently observed, suggesting that aberration of the DNA damage response is common in sporadic cancers.([@b19],[@b22],[@b23],[@b26],[@b54]--[@b62]) Promoter hypermethylation of the *BRCA1* gene is frequently observed and may be one of the predominant mechanisms for deregulation of the *BRCA1* gene.([@b62]) Furthermore, our group reported the functional inactivation of BRCA2 in cancer cells aberrantly expressing SYCP3, a cancer-testis antigen.([@b63]) Disruption of the FA pathway resulting from mutations or decreases or loss of expression due to promoter hypermethylation has been also described in various cancers.([@b64],[@b65])

As described above, both activation and inactivation of the DNA damage response are observed in cancers, and are expected to determine important properties of the DNA damage response machinery present in each cancer. The status of BRCA has been adopted as an important condition factor in current clinical trials, however, the status of other DNA damage response proteins have not yet been translated into clinical trials. In the next section, we will introduce various approaches for taking advantage of these cancer-specific properties of the DNA damage response in cancer therapy.

How Can Different DNA Damage Response Pathways be Targeted for Cancer Therapy?
==============================================================================

Because the efficacy of cancer chemotherapy and radiotherapy relies on generation of DNA damage that will be recognized and repaired by intrinsic DNA repair pathways, aberrant expression of a particular DNA damage response protein should be a biomarker of resistance or favorable response to therapies that induce the corresponding types of DNA damage.([@b66]) For example, patients with surgically treated non-small-cell lung cancer whose tumors lacked expression of ERCC1 were shown to benefit from cisplatin-based adjuvant chemotherapy in a clinical study.([@b38]) Another example is the case of RAD51, whose expression can serve as a marker of cisplatin resistance in non-small-cell lung cancer, which is consistent with the role of HR in the repair of ICL.([@b31])

In contrast, many inhibitors of the DNA damage response have been developed and some of them have been tested for their potential to enhance DNA damage-induced tumor cell killing in preclinical studies and clinical trials (Tables [2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}).

###### 

Examples of DNA damage response inhibitors in preclinical studies

  Pathway                                  Target(s)                                                           Name(s)                                             Preclinical evidence
  ---------------------------------------- ------------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------
  DNA damage                               MRE11                                                               Mirin, telomelysin                                  Sensitization to ionizing radiation
  sensors and mediators                    ATM                                                                 KU55933, KU60019, CP466722                          Sensitization to ionizing radiation and topoisomerase inhibitors
  ATR                                      Schisandrin B                                                       Sensitization to UV treatment                       
  NU6027, VE-821                           Sensitization to ionizing radiation and a variety of chemotherapy                                                       
  Cell cycle checkpoints                   Chk1                                                                SAR-020106                                          Sensitization to irinotecan and gemcitabine
  Chk2                                     VRX0466617                                                          Sensitization to ionizing radiation                 
  Non-homologous end joining               DNA-PK                                                              NU7026, NU7441                                      Sensitization to ionizing radiation and topoisomerase II inhibitors
  DNA-PK and PI3K                          KU-0060648                                                          Sensitization to etoposide and doxorubicin          
  DNA ligase IV                            SCR7                                                                Sensitization to ionizing radiation and etoposide   
  Alternative non-homologous end joining   DNA ligases I and IIIα                                              L67                                                 Sensitization to ionizing radiation and methyl methanesulfonate
  Homologous recombination (HR)            RAD51                                                               B02, A03, A10                                       Identified by high-throughput screenings of RAD51 inhibitors

###### 

Examples of DNA damage response inhibitors in clinical trials

  Pathway                                                                                                                 Target(s)                                                                                                                    Name                                                                                                                                                   Combination                                                                                                                                                                                Type of cancer           Clinical trial number   Stage                    Trial periods
  ----------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------ ----------------------- ------------------------ ---------------
  Cell cycle checkpoints                                                                                                  Chk1                                                                                                                         UCN-01                                                                                                                                                 Combination therapy                                                                                                                                                                                                                                                  
  Carboplatin                                                                                                             Advanced solid tumor                                                                                                         NCT00036777                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Irinotecan                                                                                                              Metastatic or unresectable solid tumor, triple negative breast cancer                                                        NCT00031681                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Cytarabine                                                                                                              Refractory or relapsed acute myelogenous leukemia, myelodysplastic syndrome                                                  NCT00004263                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Perifosine                                                                                                              Relapsed or refractory acute leukemia, chronic myelogenous leukemia, high risk myelodysplastic syndrome                      NCT00301938                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Gemcitabine                                                                                                             Unresectable or metastatic pancreatic cancer                                                                                 NCT00039403                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Topotecan                                                                                                               Relapsed or progressed small-cell lung cancer                                                                                NCT00098956                                                                                                                                            Phase II                                                                                                                                                                                   Completed                                                                 
  Cisplatin                                                                                                               Advanced malignant solid tumor                                                                                               NCT00012194                                                                                                                                            Phase I                                                                                                                                                                                    Terminated                                                                
  Fluorouracil                                                                                                            Metastatic pancreatic cancer                                                                                                 NCT00045747                                                                                                                                            Phase II                                                                                                                                                                                   Completed                                                                 
  Prednisone                                                                                                              Refractory solid tumor, lymphoma                                                                                             NCT00045500                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Irinotecan                                                                                                              Advanced solid tumor                                                                                                         NCT00047242                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Fluorouracil, leucovorin                                                                                                Metastatic or unresectable solid tumor                                                                                       NCT00042861                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Topotecan                                                                                                               Advanced ovarian epithelial, primary peritoneal, fallopian tube cancer                                                       NCT00072267                                                                                                                                            Phase II                                                                                                                                                                                   Completed                                                                 
  Fludarabine                                                                                                             Recurrent or refractory lymphoma or leukemia                                                                                 NCT00019838                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Fluorouracil                                                                                                            Advanced or refractory solid tumor                                                                                           NCT00004059                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Cisplatin                                                                                                               Advanced or metastatic solid tumor                                                                                           NCT00006464                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Topotecan                                                                                                               Recurrent ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cavity cancer                                 NCT00045175                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Fludarabine                                                                                                             Chronic lymphocytic leukemia or lymphocytic lymphoma                                                                         NCT00045513                                                                                                                                            Phase I, II                                                                                                                                                                                Active, not recruiting                                                    
  Monotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                          Relapsed or refractory T-cell lymphoma                                                                                       NCT00082017                                                                                                                                            Phase II                                                                                                                                                                                   Completed                                                                 
                                                                                                                          Metastatic melanoma                                                                                                          NCT00072189                                                                                                                                            Phase II                                                                                                                                                                                   Completed                                                                 
                                                                                                                          Breast cancer, lymphoma, prostatic neoplasm                                                                                  NCT00001444                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
                                                                                                                          Leukemia/lymphoma/unspecified adult solid tumor                                                                              NCT00003289                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
                                                                                                                          Advanced or metastatic kidney cancer                                                                                         NCT00030888                                                                                                                                            Phase II                                                                                                                                                                                   Active, not recruiting                                                    
  SCH900776                                                                                                               Combination therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Cytarabine                                                                                                              Relapsed acute myeloid leukemia                                                                                              NCT01870596                                                                                                                                            Phase II                                                                                                                                                                                   Until January, 2016                                                       
  Cytarabine                                                                                                              Acute myelogenous leukemia/acute lymphocytic leukemia                                                                        NCT00907517                                                                                                                                            Phase I                                                                                                                                                                                    Terminated                                                                
  Gemcitabine                                                                                                             Solid tumor/lymphoma                                                                                                         NCT00779584                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Hydroxyurea                                                                                                             Advanced solid tumors                                                                                                        NCT01521299                                                                                                                                            Phase I                                                                                                                                                                                    Withdrawn                                                                 
  LY2603618                                                                                                               Combination therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Desipramine, pemetrexed, gemcitabine                                                                                    Cancer                                                                                                                       NCT01358968                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Pemetrexed, gemcitabine                                                                                                 Advanced or metastatic solid tumor                                                                                           NCT01296568                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Pemetrexed,cisplatin                                                                                                    NSCLC                                                                                                                        NCT01139775                                                                                                                                            Phase I, II                                                                                                                                                                                Until March, 2014                                                         
                                                                                                                          Gemcitabine                                                                                                                  Pancreatic cancer                                                                                                                                      NCT00839332                                                                                                                                                                                Phase I, II              Completed                                        
                                                                                                                          Gemcitabine                                                                                                                  Solid tumor                                                                                                                                            NCT01341457                                                                                                                                                                                Phase I                  Until December, 2014                             
                                                                                                                          Pemetrexed                                                                                                                   Cancer                                                                                                                                                 NCT00415636                                                                                                                                                                                Phase I                  Completed                                        
                                                                                                                          Pemetrexed                                                                                                                   NSCLC                                                                                                                                                  NCT00988858                                                                                                                                                                                Phase II                 Until April, 2014                                
  Chk1 and Chk2                                                                                                           XL844                                                                                                                        Combination therapy                                                                                                                                                                                                                                                                                                                                                                                                         
  Gemcitabine                                                                                                             Advanced cancer, lymphoma                                                                                                    NCT00475917                                                                                                                                            Phase I                                                                                                                                                                                    Terminated                                                                
  Monotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Advanced cancer, lymphoma                                                                                               NCT00475917                                                                                                                  Phase I                                                                                                                                                Terminated                                                                                                                                                                                                                                                           
  Chronic lymphocytic leukemia                                                                                            NCT00234481                                                                                                                  Phase I                                                                                                                                                Terminated                                                                                                                                                                                                                                                           
  AZD7762                                                                                                                 Combination therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Gemcitabine                                                                                                             Solid tumor                                                                                                                  NCT00413686                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Gemcitabine                                                                                                             Solid tumor                                                                                                                  NCT00937664                                                                                                                                            Phase I                                                                                                                                                                                    Terminated                                                                
  Irinotecan                                                                                                              Solid tumor                                                                                                                  NCT00473616                                                                                                                                            Phase I                                                                                                                                                                                    Terminated                                                                
  PF-00477736                                                                                                             Combination therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Gemcitabine                                                                                                             Advanced solid tumor                                                                                                         NCT00437203                                                                                                                                            Phase I                                                                                                                                                                                    Terminated                                                                
  Non-homologous end joining                                                                                              DNA-PK and mTOR                                                                                                              CC-115                                                                                                                                                 Monotherapy                                                                                                                                                                                                                                                          
  Multiple myeloma, non-Hodgkin\'s lymphoma, glioblastoma, squamous cell carcinoma of head and neck,                      NCT01353625                                                                                                                  Phase I                                                                                                                                                Until April, 2015                                                                                                                                                                                                                                                    
  prostate cancer, Ewing\'s osteosarcoma, chronic lymphocytic leukemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Base excision repair                                                                                                    APE1                                                                                                                         TRC102                                                                                                                                                 Combination therapy                                                                                                                                                                                                                                                  
  Pemetrexed                                                                                                              Neoplasm                                                                                                                     NCT00692159                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Temozolomide                                                                                                            Lymphoma, solid tumor                                                                                                        NCT01851369                                                                                                                                            Phase I                                                                                                                                                                                    Until February, 2015                                                      
  Fludarabine                                                                                                             Relapsed or refractory hematologic malignancy                                                                                NCT01658319                                                                                                                                            Phase I                                                                                                                                                                                    Until January, 2015                                                       
  Lucanthone                                                                                                              Combination therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Radiotherapy                                                                                                            Brain metastases from NSCLC                                                                                                  NCT02014545                                                                                                                                            Phase II                                                                                                                                                                                   Until Decemcer, 2017                                                      
  Temozolomide and radiation                                                                                              Glioblastoma multiforme                                                                                                      NCT01587144                                                                                                                                            Phase II                                                                                                                                                                                   Terminated                                                                
  PARP                                                                                                                    Rucaparib (AG014688)                                                                                                         Combination therapy                                                                                                                                                                                                                                                                                                                                                                                                         
  Cisplatin                                                                                                               Triple negative breast cancer or ER/PR+, HER2− breast cancer with known BRCA1/2 mutations                                    NCT01074970                                                                                                                                            Phase II                                                                                                                                                                                   Until May, 2014                                                           
  Carboplatin                                                                                                             Advanced solid tumor                                                                                                         NCT01009190                                                                                                                                            Phase I                                                                                                                                                                                    Until Dec, 2013                                                           
  Monotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer               NCT01891344                                                                                                                  Phase II                                                                                                                                               Until December, 2015                                                                                                                                                                                                                                                 
  Solid tumor (Phase I), ovarian cancer with germline BRCA mutations (Phase II)                                           NCT01482715                                                                                                                  Phase I, II                                                                                                                                            Until March, 2014                                                                                                                                                                                                                                                    
  Platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer   NCT01968213                                                                                                                  Phase III                                                                                                                                              Until November, 2016                                                                                                                                                                                                                                                 
  BRCA-mutated locally advanced or metastatic breast cancer or advanced ovarian cancer                                    NCT00664781                                                                                                                  Phase II                                                                                                                                               Until September, 2014                                                                                                                                                                                                                                                
  Olaparib (AZD2281)                                                                                                      Combination therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Cediranib                                                                                                               Recurrent ovarian, fallopian tube, peritoneal cancer or recurrent triple-negative breast cancer                              NCT01116648                                                                                                                                            Phase I, II                                                                                                                                                                                Until May, 2014                                                           
  Abiraterone, prednisone, or prednisolone                                                                                Metastatic castration-resistant prostate cancer                                                                              NCT01972217                                                                                                                                            Phase II                                                                                                                                                                                   Until July, 2018                                                          
  Bkm120                                                                                                                  Recurrent triple-negative breast cancer or recurrent high-grade serous ovarian cancer                                        NCT01623349                                                                                                                                            Phase I                                                                                                                                                                                    Until Dec, 2014                                                           
  Radiotherapy                                                                                                            Esophageal cancer                                                                                                            NCT01460888                                                                                                                                            Phase I                                                                                                                                                                                    Until August, 2018                                                        
  Paclitaxel                                                                                                              Recurrent or metastatic gastric cancer                                                                                       NCT01063517                                                                                                                                            Phase II                                                                                                                                                                                   Completed                                                                 
  Radiotherapy with or without cisplatin                                                                                  Locally advanced NSCLC                                                                                                       NCT01562210                                                                                                                                            Phase I                                                                                                                                                                                    Until March, 2015                                                         
  Irinotecan, cisplatin, mitomycin C                                                                                      Advanced pancreatic cancer                                                                                                   NCT01296763                                                                                                                                            Phase I, II                                                                                                                                                                                Until January, 2016                                                       
  Temozolomide                                                                                                            Relapsed glioblastoma                                                                                                        NCT01390571                                                                                                                                            Phase I                                                                                                                                                                                    Until September, 2015                                                     
  Paclitaxel                                                                                                              Advanced gastric cancer                                                                                                      NCT01924533                                                                                                                                            Phase III                                                                                                                                                                                  Until December, 2017                                                      
  Carboplatin and paclitaxel                                                                                              Stage III, stage IV relapsed ovarian cancer or uterine cancer                                                                NCT01650376                                                                                                                                            Phase I, II                                                                                                                                                                                Until February, 2015                                                      
  Radiation therapy and cetuximab                                                                                         Advanced squamous cell carcinoma of the head/neck with heavy smoking histories                                               NCT01758731                                                                                                                                            Phase I                                                                                                                                                                                    Until July, 2016                                                          
  Gefitinib                                                                                                               EGFR mutation-positive advanced NSCLC                                                                                        NCT01513174                                                                                                                                            Phase I, II                                                                                                                                                                                Until June, 2015                                                          
  Temozolomide                                                                                                            Advanced Ewing\'s sarcoma                                                                                                    NCT01858168                                                                                                                                            Phase I                                                                                                                                                                                    Until July, 2017                                                          
  Carboplatin                                                                                                             Mixed muellerian cancer, cervical cancer, ovarian cancer, breast cancer, primary peritoneal cancer, fallopian tube cancer,   NCT01237067                                                                                                                                            Phase I                                                                                                                                                                                    Until September, 2014                                                     
  endometrial cancer, carcinosarcoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Carboplatin and paclitaxel                                                                                              Advanced ovarian cancer                                                                                                      NCT01081951                                                                                                                                            Phase II                                                                                                                                                                                   Until June, 2013                                                          
  Cisplatin-based chemoradiotherapy                                                                                       Locally advanced squamous cell caricinoma of the head and neck                                                               NCT01491139                                                                                                                                            Phase I                                                                                                                                                                                    Withdrawn                                                                 
  Irinotecan                                                                                                              Triple-negative metastatic breast cancer, advanced ovarian cancer                                                            NCT00535353                                                                                                                                            Phase I                                                                                                                                                                                    Until December, 2013                                                      
  Carboplatin and/or paclitaxel                                                                                           Locally advanced or metastatic colorectal cancer                                                                             NCT00516724                                                                                                                                            Phase I                                                                                                                                                                                    Until December, 2014                                                      
  Dacarbazine                                                                                                             Advanced melanoma                                                                                                            NCT00516802                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Paclitaxel                                                                                                              Metastatic triple negative breast cancer                                                                                     NCT00707707                                                                                                                                            Phase I                                                                                                                                                                                    Until December, 2012                                                      
  Liposomal doxorubicin                                                                                                   Advanced solid tumor                                                                                                         NCT00819221                                                                                                                                            Phase I                                                                                                                                                                                    Until August, 2013                                                        
  Topotecan                                                                                                               Advanced solid tumor                                                                                                         NCT00516438                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Gemcitabine                                                                                                             Pancreatic cancer                                                                                                            NCT00515866                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Bevacizumab                                                                                                             Advanced solid tumor                                                                                                         NCT00710268                                                                                                                                            Phase I                                                                                                                                                                                    Completed                                                                 
  Cisplatin                                                                                                               Advanced solid tumor                                                                                                         NCT00782574                                                                                                                                            Phase I                                                                                                                                                                                    Until December, 2014                                                      
  Carboplatin                                                                                                             Breast and ovarian cancer with BRCA mutations or family histories                                                            NCT01445418                                                                                                                                            Phase I                                                                                                                                                                                    Recruiting                                                                
  Monotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Advanced solid tumor                                                                                                    NCT01900028                                                                                                                  Phase I                                                                                                                                                Until February, 2015                                                                                                                                                                                                                                                 
  Advanced solid tumor                                                                                                    NCT01921140                                                                                                                  Phase I                                                                                                                                                Until March, 2015                                                                                                                                                                                                                                                    
  Advanced solid tumor                                                                                                    NCT01929603                                                                                                                  Phase I                                                                                                                                                Until May, 2015                                                                                                                                                                                                                                                      
  Advanced solid tumor                                                                                                    NCT01851265                                                                                                                  Phase I                                                                                                                                                Until July, 2014                                                                                                                                                                                                                                                     
  Advanced solid tumor with normal or impaired liver function                                                             NCT01894243                                                                                                                  Phase I                                                                                                                                                Until December, 2015                                                                                                                                                                                                                                                 
  Advanced solid tumor normal or impaired kidney function                                                                 NCT01894256                                                                                                                  Phase I                                                                                                                                                Until December, 2015                                                                                                                                                                                                                                                 
  Metastatic breast cancer with germline BRCA1/2 mutations                                                                NCT02000622                                                                                                                  Phase III                                                                                                                                              Until February, 2021                                                                                                                                                                                                                                                 
  Advanced castration-resistant prostate cancer                                                                           NCT01682772                                                                                                                  Phase II                                                                                                                                               Until July, 2015                                                                                                                                                                                                                                                     
  Advanced solid tumor                                                                                                    NCT01813474                                                                                                                  Phase I                                                                                                                                                Until November, 2014                                                                                                                                                                                                                                                 
  BRCA-mutated ovarian cancer after a complete or partial response following platinum-based chemotherapy                  NCT01874353                                                                                                                  Phase III                                                                                                                                              Until June, 2020                                                                                                                                                                                                                                                     
  BRCA-mutated advanced cancer                                                                                            NCT01078662                                                                                                                  Phase II                                                                                                                                               Until December, 2013                                                                                                                                                                                                                                                 
  BRCA-mutated advanced ovarian cancer following first line platinum based chemotherapy                                   NCT01844986                                                                                                                  Phase III                                                                                                                                              Until January, 2022                                                                                                                                                                                                                                                  
  Advanced Ewing\'s sarcoma                                                                                               NCT01583543                                                                                                                  Phase II                                                                                                                                               Until April, 2015                                                                                                                                                                                                                                                    
  Stage IV colorectal cancer with microsatellite instability                                                              NCT00912743                                                                                                                  Phase II                                                                                                                                               Completed                                                                                                                                                                                                                                                            
  BRCA-deficient ovarian, peritoneal, fallopian tube cancer                                                               NCT01661868                                                                                                                  Phase II                                                                                                                                               Withdrawn                                                                                                                                                                                                                                                            
  Advanced NSCLC                                                                                                          NCT01788332                                                                                                                  Phase II                                                                                                                                               Until May, 2015                                                                                                                                                                                                                                                      
  BRCA-positive advanced breast cancer                                                                                    NCT00494234                                                                                                                  Phase II                                                                                                                                               Until December, 2013                                                                                                                                                                                                                                                 
  BRCA-positive advanced ovarian cancer                                                                                   NCT00494442                                                                                                                  Phase II                                                                                                                                               Until December, 2013                                                                                                                                                                                                                                                 
  Platinum-sensitive relapsed serous ovarian cancer                                                                       NCT00753545                                                                                                                  Phase II                                                                                                                                               Completed                                                                                                                                                                                                                                                            
  Advanced solid tumor                                                                                                    NCT00572364                                                                                                                  Phase I                                                                                                                                                Completed                                                                                                                                                                                                                                                            
  Advanced or metastatic solid tumor                                                                                      NCT00633269                                                                                                                  Phase I                                                                                                                                                Completed                                                                                                                                                                                                                                                            
  Ovarian cancer                                                                                                          NCT00516373                                                                                                                  Phase I                                                                                                                                                Until December, 2014                                                                                                                                                                                                                                                 
  Advanced solid tumor                                                                                                    NCT00777582                                                                                                                  Phase I                                                                                                                                                Until March, 2014                                                                                                                                                                                                                                                    
  High grade ovarian cancer, triple-negative breast cancer, BRCA-mutated breast cancer or ovarian cancer                  NCT00679783                                                                                                                  Phase II                                                                                                                                               Until December, 2012                                                                                                                                                                                                                                                 
  BRCA-positive advanced ovarian cancer                                                                                   NCT00628251                                                                                                                  Phase II                                                                                                                                               Until December, 2013                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                       Veliparib (ABT-888)                                                                                                                                    Combination therapy                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                       Gemcitabine, cisplatin                                                                                                                                 Locally advanced or metastatic pancreatic cancer with BRCA or PALB2 mutations                                                                                                              NCT01585805              Phase II                Until July, 2017         
                                                                                                                                                                                                                                                       Temozolomide or combination with carboplatin and paclitaxel                                                                                            Locally recurrent or metastatic breast cancer with BRCA mutations                                                                                                                          NCT01506609              Phase II                Until May, 2015          
                                                                                                                                                                                                                                                       Radiotherapy and temozolomide                                                                                                                          Newly diagnosed childhood diffuse pontine glioma                                                                                                                                           NCT01514201              Phase I, II             Until August, 2019       
                                                                                                                                                                                                                                                       Radiotherapy                                                                                                                                           Advanced solid malignancies with peritoneal carcinomatosis                                                                                                                                 NCT01264432              Phase I                 Until April, 2014        
                                                                                                                                                                                                                                                       Bendamustine, rituximab                                                                                                                                Advanced lymphoma, multiple myeloma, or solid tumors                                                                                                                                       NCT01326702              Phase I, II             Until November, 2015     
                                                                                                                                                                                                                                                       Topotecan                                                                                                                                              Relapsed epithelial ovarian, primary fallopian tube, or primary peritoneal cancer with negative or unknown BRCA status                                                                     NCT01690598              Phase I, II             Until April, 2015        
                                                                                                                                                                                                                                                       Gemcitabine and radiotherapy                                                                                                                           Locally advanced, unresectable pancreatic cancer                                                                                                                                           NCT01908478              Phase I                 Until July, 2019         
                                                                                                                                                                                                                                                       Dinaciclib with or without carboplatin                                                                                                                 Advanced solid tumors with BRCA mutations                                                                                                                                                  NCT01434316              Phase I                 Until January, 2016      
                                                                                                                                                                                                                                                       Radiotherapy, carboplatin, paclitaxel                                                                                                                  Stage III NSCLC that cannot be removed by surgery                                                                                                                                          NCT01386385              Phase I, II             Until December, 2016     
                                                                                                                                                                                                                                                       Doxorubicin, carboplatin, bevacizumab                                                                                                                  Recurrent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer                                                                                                              NCT01459380              Phase I                 Until August, 2015       
                                                                                                                                                                                                                                                       Cisplatin, gemcitabine                                                                                                                                 Advanced biliary, pancreatic, urothelial, NSCLC                                                                                                                                            NCT01282333              Phase I                 Terminated               
                                                                                                                                                                                                                                                       Cisplatin, vinorelbine                                                                                                                                 Recurrent and/or metastatic breast cancer with BRCA mutations, triple-negative breast cancer                                                                                               NCT01104259              Phase I                 Until September, 2014    
                                                                                                                                                                                                                                                       Mitomycin C                                                                                                                                            Metastatic, unresectable, or recurrent solid tumor                                                                                                                                         NCT01017640              Phase I                 Until June, 2014         
                                                                                                                                                                                                                                                       Capecitabine, radiotherapy                                                                                                                             Locally advanced rectal cancer                                                                                                                                                             NCT01589419              Phase I                 Until June, 2015         
                                                                                                                                                                                                                                                       Cyclophosphamide                                                                                                                                       Locally advanced or metastatic HER2-negative breast cancer                                                                                                                                 NCT01351909              Phase I, II             Until May, 2015          
                                                                                                                                                                                                                                                       Docetaxel, cisplatin, fluorouracil, radiotherapy, hydroxyurea, paclitaxel                                                                              Stage IV head and neck cancer Solid tumor                                                                                                                                                  NCT01193140              Phase II                Completed                
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                                                                                                                                                                                                                      NCT01711541              Phase I, II             Until October, 2014      
                                                                                                                                                                                                                                                       Cisplatin, etoposide                                                                                                                                   Extensive stage small-cell lung cancer, metastatic large cell neuroendocrine NSCLC, small-cell carcinoma of unknown primary or extrapulmonary origin                                       NCT01642251              Phase I, II             Until January, 2018      
                                                                                                                                                                                                                                                       Paclitaxel, carboplatin                                                                                                                                Metastatic, unresectable solid tumor with liver or kidney dysfunction                                                                                                                      NCT01366144              Phase I                 Until July, 2015         
                                                                                                                                                                                                                                                       Oxaliplatin, capecitabine                                                                                                                              BRCA-related malignancy, metastatic colorectal cancer, metastatic ovarian cancer,                                                                                                          NCT01233505              Phase I                 Until July, 2014         
                                                                                                                                                                                                                                                       metastatic gastrointestinal malignancies in which oxaliplatin has shown some activity                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                       Carboplatin                                                                                                                                            Stage III or stage IV breast cancer with BRCA mutations                                                                                                                                    NCT01149083              Phase II                Until June, 2014         
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Acute leukemia                                                                                                                                                                             NCT01139970              Phase I                 Until October, 2013      
                                                                                                                                                                                                                                                       Carboplatin, paclitaxel                                                                                                                                Solid tumor                                                                                                                                                                                NCT01617928              Phase I                 Completed                
                                                                                                                                                                                                                                                       Topotecan                                                                                                                                              Recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, unspecified solid tumor                                                                                             NCT01012817              Phase I, II             Until June, 2018         
                                                                                                                                                                                                                                                       Carboplatin, paclitaxel                                                                                                                                Advanced NSCLC                                                                                                                                                                             NCT01560104              Phase II                Until September, 2014    
                                                                                                                                                                                                                                                       Carboplatin                                                                                                                                            HER2-negative metastatic or locally advanced breast cancer                                                                                                                                 NCT01251874              Phase I                 Until September, 2013    
                                                                                                                                                                                                                                                       Paclitaxel, cisplatin                                                                                                                                  Advanced, persistent, or recurrent cervical cancer                                                                                                                                         NCT01281852              Phase I, II             Until March, 2020        
                                                                                                                                                                                                                                                       Topotecan with or without carboplatin                                                                                                                  Relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive myeloproliferative disorders                                                                                NCT00588991              Phase I                 Until December, 2012     
                                                                                                                                                                                                                                                       Abiraterone, prednisone                                                                                                                                Metastatic hormone-resistant prostate cancer                                                                                                                                               NCT01576172              Phase II                Until February, 2014     
                                                                                                                                                                                                                                                       Topotecan and filgrastim or pegfilgrastim                                                                                                              Persistent or recurrent cervical cancer                                                                                                                                                    NCT01266447              Phase II                Until November, 2016     
                                                                                                                                                                                                                                                       Gemcitabine                                                                                                                                            Solid tumor                                                                                                                                                                                NCT01154426              Phase I                 Until October, 2013      
                                                                                                                                                                                                                                                       Modified FOLFOX6                                                                                                                                       Metastatic pancreatic cancer                                                                                                                                                               NCT01489865              Phase I, II             Until December, 2014     
                                                                                                                                                                                                                                                       FOLFIRI                                                                                                                                                Advanced gastric cancer                                                                                                                                                                    NCT01123876              Phase I                 Until December, 2014     
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Recurrent or refractory childhood central nervous system tumor                                                                                                                             NCT00946335              Phase I                 Until October, 2011      
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Hepatocellular carcinoma                                                                                                                                                                   NCT01205828              Phase II                Until December, 2013     
                                                                                                                                                                                                                                                       Carboplatin, paclitaxel                                                                                                                                Advanced solid tumor                                                                                                                                                                       NCT01281150              Phase I                 Until December, 2013     
                                                                                                                                                                                                                                                       Carboplatin, paclitaxel, doxorubicin, cyclophosphamide                                                                                                 Stage IIb-IIIc triple-negative breast cancer                                                                                                                                               NCT01818063              Phase II                Until April, 2018        
                                                                                                                                                                                                                                                       Floxuridine                                                                                                                                            Metastatic epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer                                                                                                         NCT01749397              Phase I                 Until March, 2016        
                                                                                                                                                                                                                                                       Liposomal doxorubicin                                                                                                                                  Recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer or metastatic triple-negative breast cancer                                                                  NCT01145430              Phase I                 Until March, 2014        
                                                                                                                                                                                                                                                       Bortezomib, dexamethasone                                                                                                                              Relapsed refractory multiple myeloma                                                                                                                                                       NCT01495351              Phase I                 Until October, 2013      
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Recurrent small-cell lung cancer                                                                                                                                                           NCT01638546              Phase II                Until June, 2017         
                                                                                                                                                                                                                                                       Cyclophosphamide, doxorubicin                                                                                                                          Metastatic or unresectable solid tumor, non-Hodgkin\'s lymphoma                                                                                                                            NCT00740805              Phase I                 Until December, 2013     
                                                                                                                                                                                                                                                       Whole brain radiation                                                                                                                                  Brain metastases from NSCLC                                                                                                                                                                NCT01657799              Phase II                Until November, 2014     
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Recurrent high grade serous ovarian, fallopian tube, or primary peritoneal cancer                                                                                                          NCT01113957              Phase II                Completed                
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Metastatic or locally advanced breast cancer and BRCA1/2-associated breast cancer                                                                                                          NCT01009788              Phase II                Until December, 2014     
                                                                                                                                                                                                                                                       Carboplatin, paclitaxel                                                                                                                                Advanced cancer with liver or kidney problems                                                                                                                                              NCT01419548              Phase I                 Withdrawn                
                                                                                                                                                                                                                                                       Whole brain radiation                                                                                                                                  Cancer with brain metastases                                                                                                                                                               NCT00649207              Phase I                 Completed                
                                                                                                                                                                                                                                                       Radiotherapy                                                                                                                                           Inflammatory or loco-regionally recurrent breast cancer                                                                                                                                    NCT01477489              Phase I                 Until December, 2016     
                                                                                                                                                                                                                                                       Carboplatin, paclitaxel, bevacizumab                                                                                                                   Newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer                                                                                             NCT00989651              Phase I                 Until July, 2014         
                                                                                                                                                                                                                                                       Carboplatin, paclitaxel                                                                                                                                Advanced solid tumor or BRCA1/2-associated advanced solid tumor                                                                                                                            NCT00535119              Phase I                 Until October, 2012      
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Colorectal cancer                                                                                                                                                                          NCT01051596              Phase II                Until December, 2013     
                                                                                                                                                                                                                                                       Cyclophosphamide                                                                                                                                       Refractory BRCA-positive ovarian, primary peritoneal or ovarian high-grade serous carcinoma, fallopian tube cancer, triple-negative breast cancer, and low-grade non-Hodgkin\'s lymphoma   NCT01306032              Phase II                Until November, 2014     
                                                                                                                                                                                                                                                       Irinotecan                                                                                                                                             Metastatic or unresectable solid tumor, lymphoma                                                                                                                                           NCT00576654              Phase I                 Until December, 2013     
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Recurrent or refractory childhood central nervous system tumor                                                                                                                             NCT00994071              Phase I                 Completed                
                                                                                                                                                                                                                                                       Cyclophosphamide                                                                                                                                       Refractory solid tumor or lymphoma                                                                                                                                                         NCT01445522              Phase I                 Completed                
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Recurrent high-grade glioma                                                                                                                                                                NCT01026493              Phase I, II             Until February, 2014     
                                                                                                                                                                                                                                                       Cyclophosphamide                                                                                                                                       Solid tumor or lymphoma that did not respond to previous therapy                                                                                                                           NCT00810966              Phase I                 Active, not recruiting   
                                                                                                                                                                                                                                                       Radiotherapy, temozolomide                                                                                                                             Grade IV astrocytoma                                                                                                                                                                       NCT00770471              Phase I, II             Completed                
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Metastatic prostate cancer                                                                                                                                                                 NCT01085422              Phase I                 Completed                
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Advanced non-hematologic tumor                                                                                                                                                             NCT00526617              Phase I                 Completed                
                                                                                                                                                                                                                                                       Topotecan                                                                                                                                              Refractory solid tumor or lymphoma                                                                                                                                                         NCT00553189              Phase I                 Completed                
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Metastatic melanoma                                                                                                                                                                        NCT00804908              Phase II                Until March, 2014        
                                                                                                                                                                                                                                                       Carboplatin, gemcitabine                                                                                                                               Advanced solid tumor                                                                                                                                                                       NCT01063816              Phase I                 Until September, 2014    
                                                                                                                                                                                                                                                       Radiotherapy                                                                                                                                           Breast cancer                                                                                                                                                                              NCT01618357              Phase I                 Until April, 2016        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                       Monotherapy                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                       Solid tumor                                                                                                                                            NCT01199224                                                                                                                                                                                Phase I                  Completed                                        
                                                                                                                                                                                                                                                       Locally advanced or metastatic pancreatic cancer                                                                                                       NCT01585805                                                                                                                                                                                Phase II                 Until July, 2017                                 
                                                                                                                                                                                                                                                       Metastatic, unresectable, or recurrent solid tumors                                                                                                    NCT01017640                                                                                                                                                                                Phase I                  Until June, 2014                                 
                                                                                                                                                                                                                                                       Stage III or Stage IV breast cancer with BRCA mutations                                                                                                NCT01149083                                                                                                                                                                                Phase II                 Until June, 2014                                 
                                                                                                                                                                                                                                                       BRCA-mutated metastatic or unresectable malignancy, high grade serous ovarian, fallopian tube, or peritoneal cancer                                    NCT01853306                                                                                                                                                                                Phase I                  Until January, 2015                              
                                                                                                                                                                                                                                                       BRCA-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer                                                                          NCT01540565                                                                                                                                                                                Phase II                 Until April, 2014                                
                                                                                                                                                                                                                                                       Advanced solid tumor                                                                                                                                   NCT02009631                                                                                                                                                                                Phase I                  Until December, 2014                             
                                                                                                                                                                                                                                                       BRCA-related malignancy, platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer or basal-like breast cancer, advanced solid tumor   NCT00892736                                                                                                                                                                                Phase I                  Until December, 2013                             
                                                                                                                                                                                                                                                       Relapsed epithelial ovarian, primary fallopian or primary peritoneal cancer with BRCA mutations                                                        NCT01472783                                                                                                                                                                                Phase I, II              Until December, 2015                             
                                                                                                                                                                                                                                                       Chronic lymphocytic leukemia, follicular lymphoma, unspecified solid tumor                                                                             NCT00387608                                                                                                                                                                                Phase I                  Completed                                        
                                                                                                                                                                                                                                                       Invasive breast cancer                                                                                                                                 NCT01042379                                                                                                                                                                                Phase II                 Until November, 2014                             
                                                                                                                                                                                                                                                       Advanced solid tumor                                                                                                                                   NCT01827384                                                                                                                                                                                Phase II                 Until March, 2017                                
                                                                                                                                                                                                                                                       INO-1001                                                                                                                                               Combination therapy                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Unresectable melanoma                                                                                                                                                                      NCT00272415              Phase I                 Terminated               
                                                                                                                                                                                                                                                       MK4827                                                                                                                                                 Combination therapy                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                       Liposomal doxorubicin                                                                                                                                  Advanced solid tumor, platinum-resistant high grade serous ovarian cancer                                                                                                                  NCT01227941              Phase I                 Terminated               
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Advanced solid tumor, glioblastoma multiforme, melanoma                                                                                                                                    NCT01294735              Phase I                 Completed                
                                                                                                                                                                                                                                                       Carboplatin, paclitaxel, liposomal doxorubicin                                                                                                         Advanced solid tumor                                                                                                                                                                       NCT01110603              Phase I                 Terminated               
                                                                                                                                                                                                                                                       Monotherapy                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                       Advanced solid tumor                                                                                                                                   NCT01226901                                                                                                                                                                                Phase I                  Terminated                                       
                                                                                                                                                                                                                                                       Mantle cell lymphoma                                                                                                                                   NCT01244009                                                                                                                                                                                Phase II                 Withdrawn                                        
                                                                                                                                                                                                                                                       Advanced solid tumors, chronic lymphocytic leukemia, T-cell-prolymphocytic leukemia                                                                    NCT00749502                                                                                                                                                                                Phase I                  Completed                                        
                                                                                                                                                                                                                                                       Advanced HER2-negative, germline BRCA mutation-positive breast cancer                                                                                  NCT01905592                                                                                                                                                                                Phase III                Until October, 2015                              
                                                                                                                                                                                                                                                       CEP-9722                                                                                                                                               Combination therapy                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                       Gemcitabine, cisplatin                                                                                                                                 Advanced solid tumor or mantle cell lymphoma                                                                                                                                               NCT01345357              Phase I                 Completed                
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Advanced solid tumor                                                                                                                                                                       NCT00920595              Phase I                 Completed                
                                                                                                                                                                                                                                                       Monotherapy                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                       Advanced solid tumor                                                                                                                                   NCT01311713                                                                                                                                                                                Phase I, II              Terminated                                       
                                                                                                                                                                                                                                                       Advanced solid tumor                                                                                                                                   NCT00920595                                                                                                                                                                                Phase I                  Completed                                        
                                                                                                                                                                                                                                                       E7016                                                                                                                                                  Combination therapy                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Advanced solid tumor                                                                                                                                                                       NCT01127178              Phase I                 Completed                
                                                                                                                                                                                                                                                       Temozolomide                                                                                                                                           Wild-type BRAF stage IV melanoma, unresectable stage III melanoma                                                                                                                          NCT01605162              Phase II                Until March, 2014        
                                                                                                                                                                                                                                                       BMN673                                                                                                                                                 Monotherapy                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                       Acute myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, mantle cell lymphoma                                                   NCT01399840                                                                                                                                                                                Phase I                  Until June, 2013                                 
                                                                                                                                                                                                                                                       Advanced or recurrent solid tumor                                                                                                                      NCT01286987                                                                                                                                                                                Phase I                  Until June, 2013                                 
                                                                                                                                                                                                                                                       Advanced solid tumor with deleterious BRCA mutations                                                                                                   NCT01989546                                                                                                                                                                                Phase I, II              Until August, 2016                               
                                                                                                                                                                                                                                                       Advanced breast cancer with BRCA mutations                                                                                                             NCT01945775                                                                                                                                                                                Phase III                Until June, 2016                                 

For current status and information of clinical trials, refer to <http://clinicaltrials.gov/>, a service of the US National Institutes of Health. NSCLC, non-small-cell lung cancer.

Inhibitors of ATM/ATR and the MRN complex
-----------------------------------------

As ATM and the MRN complex play central roles as sensors or mediators in the DNA damage response, these molecules have been considered to be promising targets for radiosensitization or chemosensitization.([@b67]) Several promising ATM inhibitors have been developed (Table [2](#tbl2){ref-type="table"}). KU55933, the first specific inhibitor of ATM, inhibits radiation-induced ATM-dependent phosphorylation events and sensitizes cancer cells to radiation and topoisomerase inhibitors.([@b67]) KU60019, an improved analog of KU55933, inhibits the DNA damage response and effectively radiosensitizes human glioma cells.([@b68]) Mirin is an inhibitor of the MRN complex, which prevents MRN-dependent activation of ATM without affecting ATM protein kinase activity and inhibits MRE11-associated exonuclease activity.([@b67]) Telomelysin is another inhibitor that inhibits the MRN complex through the adenoviral E1B-55 kDa protein.([@b67]) The therapeutic outcomes of these agents remain to be tested in clinical trials. Although the long search for selective inhibitors of ATR has not yet paid off, schisandrin B was recently identified as a moderate selective ATR inhibitor, although it will also affect ATM at high concentrations.([@b69]) Recently, two novel ATR inhibitors, NU6027 and VE-821, were also shown to sensitize cells to a variety of DNA-damaging agents in preclinical studies.([@b70],[@b71])

Inhibitors of Chk1/Chk2 and CDC25
---------------------------------

As the triggering of cell cycle checkpoints is crucial in the DNA damage response, these checkpoints have also been widely investigated as a potential target for cancer therapy (Table [3](#tbl3){ref-type="table"}).([@b72]) Among the inhibitors for Chk1 and/or Chk2, UCN-01 was the first to enter clinical trials, but it was discontinued due to toxicities such as symptomatic hypotension and neutropenia and a lack of convincing efficacy after phase II trials.([@b72]) Other Chk1/Chk2 inhibitors with improved specificities, including XL844 and AZD7762, also entered clinical trials but failed to achieve a good response.([@b72]) The selective Chk1 inhibitor SCH900776 has been used in phase I trials for acute leukemia in combination with cytarabine and for solid tumors in combination with gemcitabine, and showed some partial responses and stable disease.([@b72]) The Chk1 inhibitor LY2603618 and the dual Chk1/Chk2 inhibitor LY2606368 are also currently being tested in early clinical trials. CDC25 phosphatases, the key factors in cyclin-dependent kinase activation crucial for cell cycle regulation, are also considered to represent promising novel targets in cancer therapy. CDC25 inhibitors have also been developed, and some have entered into clinical trials, although the clinical data is limited.([@b73])

Inhibition of NHEJ by DNA-PK inhibitors
---------------------------------------

Regarding NHEJ, inhibitors of DNA-PK, including NU7026 and NU7441, were found to induce extreme sensitivity to ionizing radiation as well as DNA-damaging agents in preclinical studies (Table [2](#tbl2){ref-type="table"}).([@b74]) However, the therapeutic efficacy of DNA-PK inhibitors depends on the expression levels of DNA-PK in cancer cells versus normal cells, and their clinical application is currently restricted because of their toxicity to normal cells. The dual mTOR and DNA-PKcs inhibitor CC-115 is undergoing early clinical evaluation (Table [3](#tbl3){ref-type="table"}). KU-0060648 is a potent dual inhibitor of DNA-PK and PI-3K, which has recently been reported to enhance etoposide and doxorubicin cytotoxicity (Table [2](#tbl2){ref-type="table"}).([@b75])

Inhibition of NHEJ or alt-NHEJ by DNA ligase inhibitors
-------------------------------------------------------

DNA ligases are required for both NHEJ and alt-NHEJ pathways as well as other DNA repair pathways such as BER and NER. Small molecule inhibitors of human DNA ligases have been identified and shown to be cytotoxic and also to enhance the cytotoxicity of DNA-damaging agents. SCR7 is an inhibitor of DNA ligase IV, which is involved in the NHEJ pathway. SCR7 reduces cell proliferation in a DNA ligase IV-dependent manner and increases the tumor-inhibitory effects of agents that cause DSBs.([@b76]) L67 is an inhibitor of DNA ligases I and IIIα, which are involved in the alt-NHEJ pathway as well as BER and NER. The levels of the alt-NHEJ proteins such as DNA ligase IIIα and WRN are reported to be elevated in BCR-ABL-positive CML cell lines,([@b77]) so inhibition of alt-NHEJ factors may be an additional therapeutic approach in BCR-ABL-positive CML, which is usually treated by tyrosine kinase inhibitors. Indeed, CML cell lines with increased alt-NHEJ were shown to be hypersensitive to the combination of L67 and PARP inhibitor.([@b78])

Inhibitors of RAD51 and tyrosine kinases regulating HR
------------------------------------------------------

With respect to HR, there are currently few inhibitors that directly target HR proteins. Along with the RAD51 inhibitors that were recently identified (Table [2](#tbl2){ref-type="table"},[@b79]) the molecules that indirectly regulate HR may also be candidate targets for inhibiting HR. For example, the non-receptor tyrosine kinase c-Abl is activated by ATM in response to DNA damage, and subsequently phosphorylates RAD51.([@b80]) Oncogenic fusion tyrosine kinases, such as BCR-ABL, TEL-ABL, TEL-JAK2, TEL-PDGFβR, and NPM-ALK, enhance the expression levels and/or tyrosine phosphorylation of RAD51.([@b81],[@b82]) From these findings, inhibitors of oncogenic tyrosine kinases are expected to sensitize cancer cells to DNA-damaging agents. Consistent with this hypothesis, treatments with the tyrosine inhibitor imatinib have been shown to enhance sensitivity to DNA crosslinking agents and ionizing radiation in cancer cells.([@b81]) Furthermore, targeting RAD51 was shown to overcome imatinib resistance in CML cells.([@b83])

Inhibitors of histone deacetylases, heat shock protein 90, and DSB repair
-------------------------------------------------------------------------

Histone deacetylases (HDACs) are powerful regulators of the stability of the genome, and many HDAC inhibitors are shown to downregulate multiple components of the DNA damage response and repair, including HR, NHEJ, the MRN complex, and ATM.([@b84]) Thus, the use of HDAC inhibitors in combination with DNA-damaging agents may be an area of great interest with potential clinical utility. The HDAC inhibitor PCI-24781 caused increased apoptosis by inhibiting RAD51-mediated HR when used in combination with the PARP inhibitor PJ34 in a preclinical study.([@b85]) The inhibitor of heat shock protein 90, 17-allylamino-17-demethoxygeldanamycin, radiosensitizes human tumor cell lines by inhibiting RAD51-mediated HR.([@b86]) Curcumin is a natural product that has been tested for its chemosensitizing potential, and sensitizes cancer cells to PARP inhibitors by inhibiting NHEJ, HR, and the DNA damage checkpoint.([@b87])

Inhibitors of PARP and APE1 in combination with DNA-damaging agents
-------------------------------------------------------------------

Inhibitors of PARP, which inhibit the BER and SSB repair pathways, are the most advanced and promising drugs that target DNA repair.([@b88]) A number of clinical trials using PARP inhibitors are currently underway (Table [3](#tbl3){ref-type="table"}). Inhibitors of PARP were first tried in combination with DNA-damaging agents. Some clinical responses were observed in the phase I and II trials of the PARP inhibitor rucaparib in combination with temozolomide.([@b89],[@b90]) Further clinical trials of PARP inhibitors have been carried out in combination with various DNA-damaging agents and/or ionizing radiation (Table [3](#tbl3){ref-type="table"}). Inhibitors of another BER protein APE1 are also being tested in combination with DNA-damaging agents in clinical trials (Table [3](#tbl3){ref-type="table"}).

Using PARP inhibitors as single agents in BRCA-deficient cancers based on the principle of synthetic lethality
--------------------------------------------------------------------------------------------------------------

In 2005, PARP inhibitors were shown to selectively inhibit the growth of cells with defects in either the *BRCA1* or *BRCA2* genes, suggesting a new use of PARP inhibitors as single agents.([@b91],[@b92]) A possible explanation for this lethality is as follows. The cancer cells with defects in the *BRCA* gene are defective in HR, as the wild-type *BRCA* allele is absolutely lost. However, HR is intact in normal cells of the same patients who carry one wild-type *BRCA* allele and one mutant *BRCA* allele. Inhibition of PARP1 results in the accumulation of SSBs, which are converted to lethal DSBs that require HR for their repair. Although such lesions would be repaired by HR in normal cells, they are not repaired in BRCA1- or BRCA2-deficient cancer cells because these cells are defective in HR repair, and thus the tumor cells are led to death. This concept is termed synthetic lethality, namely, the process by which defects in two different genes or pathways together result in cell death while defects in one of the two different genes or pathways do not affect viability (Fig. [3](#fig03){ref-type="fig"}).([@b3]) This attractive new therapeutic strategy based on the principle of synthetic lethality relies on the frequent defects in the DNA damage response observed in cancer as summarized in the previous chapter and Table [1](#tbl1){ref-type="table"}, in which alternative DNA damage response pathways may be activated to allow cancer cells to survive in the presence of genotoxic stress. Because this strategy targets the cancer-specific aberrations in the DNA damage response, it will cause few or no toxicities on normal cells. The first report of a clinical trial of a PARP inhibitor as a single agent in patients with *BRCA* mutations was the phase I study of the oral PARP inhibitor olaparib.([@b93]) It established the safety of olaparib as a single agent, and good responses were observed in patients with *BRCA*-mutated breast, ovarian, or prostate tumors. In subsequent phase II studies, approximately one-third of the patients with breast or ovarian cancer with germline *BRCA* mutations showed a favorable response to the drug with no severe toxicities.([@b94]) Several other PARP inhibitors are currently being investigated in patients with germline *BRCA* mutations as single agents (Table [3](#tbl3){ref-type="table"}). It is likely that PARP inhibitors have significant benefit to at least a subpopulation of cancer patients with defects in BRCA-mediated HR pathways.

![Principle of synthetic lethality. DNA damage is often processed by multiple DNA repair pathways. In the example shown here, pathways A and B are both intact in normal cells, whereas pathway A is defective in cancer cells. (a) In the absence of the pathway B inhibitor, cancer cells can survive, because the defect in pathway A is compensated by the alternative pathway B. (b) When the cells are treated with the pathway B inhibitor, both pathways will be blocked in cancer cells, which will result in cell death. However, normal cells will not be affected, because inhibition of pathway B will be compensated by pathway A.](cas0105-0370-f3){#fig03}

Using PARP inhibitors as single agents in cancers with no *BRCA* mutations
--------------------------------------------------------------------------

The potential for PARP inhibitors as single agents has also been tested in clinical trials of cancers with no germline *BRCA* mutations, such as high-grade serous ovarian cancers and triple-negative breast cancers.([@b95]) Inhibitors of PARP were also effective in a subset of cancers with no germline *BRCA* mutations, suggesting that there may be a subset of sporadic cancers that show features of "BRCAness," which may show good response to PARP inhibitors.([@b96]) Indeed, cancer cells expressing the cancer-testis antigen SYCP3, in which BRCA2 is functionally inactivated, as described above, show extreme hypersensitivity to a PARP inhibitor.([@b63]) Defects in other HR-related proteins such as RAD51, RAD54, and RPA also confer selective sensitivity to PARP inhibition.([@b97]) Moreover, defects in the DNA damage response proteins, such as NBS1, MRE11, ATR, ATM, FANCD2, FANCA, FANCC, Chk1, Chk2, and ERCC1, also confer selective sensitivity to PARP inhibition.([@b97],[@b98])

Exploitation of other synthetic lethalities by DNA damage response
------------------------------------------------------------------

Taking advantage of the dysregulated DNA damage response in cancer using the synthetic lethality approach may be one of the most promising prospects for the future of cancer treatment. From this point of view, many efforts have been made to identify defects of two different DNA damage response genes or pathways that are synthetically lethal when combined. For example, ATM inhibition is shown to be synthetically lethal with FA pathway deficiency.([@b99]) The suggested explanation for this lethality is as follows. The FA pathway-deficient cancer cells are defective in the repair of DNA replication fork stalling, which is normally repaired by ATR and the FA pathway. In FA pathway-deficient conditions, the stalled fork will collapse and form a DSB that will alternatively activate an ATM-dependent DNA damage response. Inhibition of ATM in such FA pathway-deficient cells will leave no alternative mechanism for repair, leading to cell death. The FA pathway-deficient cells are also hypersensitive to Chk1 silencing,([@b100]) which may be explained by the hyperdependence of the FA pathway-deficient cells on G~2~/M checkpoint activation mediated by Chk1 for viability. Because defects in the FA pathway are frequently observed in a number of different types of cancer (Table [1](#tbl1){ref-type="table"},[@b64],[@b65]) the use of ATM inhibitors or Chk1 inhibitors in FA pathway-deficient tumors will be a promising approach that should be evaluated in clinical trials in the future. In another example, RAD54B deficiency is shown to be synthetically lethal in cells with reduced Flap endonuclease 1 expression, but the mechanisms of this lethality remain to be elucidated.([@b101]) Recently, inhibition of APE1 was shown to be synthetically lethal in BRCA- and ATM-deficient cells, presenting a novel model for APE inhibition as a synthetic lethal strategy in cells deficient in DSB repair.([@b102]) Briefly, APE1 inhibition leads to AP site accumulation and results in indirect generation of SSBs that are eventually converted to toxic DSBs, which cannot be repaired in cells deficient in DSB repair. The APE1 inhibitors are being tested in combination with DNA-damaging agents in current clinical trials, and they may be evaluated further as a synthetic lethal strategy. More recently, inactivation of the HR protein RAD52 was shown to be synthetically lethal with deficiencies in BRCA2, BRCA1, and PALB2.([@b103],[@b104]) This lethal effect may be due to the loss of RAD51-dependent HR function mediated by the BRCA1--PALB2--BRCA2 complex, because human RAD52 is suggested to function in an independent and alternative repair pathway of RAD51-dependent HR when deficiencies exist in BRCA1, PALB2, or BRCA2. As no inactivating mutations of RAD52 have been documented in human sporadic cancers, inhibition of RAD52 could be an attractive strategy for improving cancer therapy in the BRCA- or PALB2-defective subgroup of cancers. Although no inhibitors of RAD52 have been developed yet, it would be of great interest to assess the effects of inhibition of RAD52 on cancer-specific killing of the cancers with "BRCAness" profiles and compare them with those of PARP inhibitors in future clinical trials. There might be additional synthetic lethalities to be discovered and exploited in future.

Current Limitations and Future Perspectives
===========================================

Although the data from clinical trials of the inhibitors of DNA damage response, including PARP inhibitors, seem encouraging, we should note that the use of PARP inhibitors also faces significant limitations.

The first limitation is the evolution of resistance. In the case of using PARP inhibitors in cancer cells carrying mutations in *BRCA1* or *BRCA2*, the drug resistance can be caused by secondary mutations in the *BRCA1* or *BRCA2* gene that restore the open reading frame of the gene and enable the generation of functional BRCA proteins possessing the ability to repair DNA damage caused by PARP inhibitors.([@b105]--[@b107]) Other suggested mechanisms underlying the resistance to PARP inhibitors include the loss of 53BP1 expression in BRCA-deficient cells and the upregulation of genes that encode P-glycoprotein efflux pumps,([@b108]--[@b111]) although the importance of these factors in clinical resistance to PARP inhibitors has not been elucidated. In future clinical trials, it would be desirable to periodically monitor the sequences of *BRCA1* and *BRCA2* and the expression levels of the key proteins such as 53BP1 or P-glycoprotein efflux pumps.

The second limitation is the lack of reliable biomarkers of response or resistance to the inhibitors. There is a pressing need to identify biomarkers to predict the response to the inhibitors. Regarding the sensitivities to PARP inhibitors, elevated levels of PARP and CDK12 deficiency are suggested to be possible biomarkers for favorable responses.([@b45],[@b112]) We should also keep in mind that many factors might affect the DNA damage response and take into account the complexity of the networks regulating DNA repair. For instance, most cancer cells grow under hypoxia, a condition that activates hypoxia inducible factor-1 (HIF-1). Because HIF-1 contributes to therapy resistance, it is considered an attractive target molecule for cancer therapy. Diverse functional interactions between HIF-1 and the DNA damage response have also been described,([@b113]) so the efficacy of the combination of HIF-1 inhibitors and inhibitors of the DNA damage response proteins should be examined in the future.

Conclusions
===========

Defects or upregulation of the proteins involved in DNA damage response and repair are common in cancers, and may be induced by both genetic and epigenetic causes. Inhibition of the DNA damage response proteins can be used to enhance chemotherapy and radiotherapy, and also to selectively kill cancer cells showing deficiencies in particular DNA repair pathway(s) based on the principle of synthetic lethality. Inhibition of PARP in BRCA-defective cancers seemed effective in early clinical trials. Better understanding of the basic biology underlying the DNA damage response and the mechanisms responsible for its dysregulation in cancer will provide exciting opportunities for new and efficient cancer therapy targeting the DNA damage response.
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